At this point we need to introduce the additional concept of name-to-structure (n2s). This is an important determinant of both ABNES and D-C utility. Using the example again from a paper this would mean that both the code name and the INN would be included in the D-C capture record (i.e. n2s) even if 50 analogues were also tested. Other examples that present particular ABNES problems are review articles, synthetic chemistry papers and patents. A review could exemplify 20 lead compounds all with different company code numbers and/or INNs, an extended synthesis report could give rise to 200 D-C records and a patent could have over 500. Discerning the ABNES for patents can be especially problematic since frankly obfuscatory titles and abstracts are common (e.g. "Novel Compounds")